Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/ II MORPHEUS Trial
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3528 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Andrew H Ko und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Enrolling adequate numbers of patients into the control arm of randomized controlled trials (RCTs) often presents barriers. There is interest in leveraging real‐world data (RWD) from electronic health records (EHRs) to construct external control (EC) arms to supplement RCT control arms and form hybrid control (HC) arms. This investigation showed the use of an HC arm in second‐line metastatic pancreatic ductal adenocarcinoma (PDAC). The RCT experimental arm (atezolizumab + PEGylated recombinant human hyaluronidase (Atezo + PEGPH20)) was compared with an HC arm consisting of patients treated with modified FOLFOX6 or gemcitabine/nab‐paclitaxel from the MORPHEUS PDAC internal control arm supplemented with data from a nationwide EHR‐derived de‐identified database as the EC arm. The EC arm was constructed by applying key inclusion/exclusion criteria from the MORPHEUS PDAC trial to patients from the real‐world cohort. Baseline variables were balanced using propensity score matching and covariate adjustment. Three analysis approaches—Cox model with pooled‐control data, Cox model with control arm‐specific frailty, and Bayesian analysis using a commensurate prior—were assessed. Overall survival was similar between the treatment arms. The direction and magnitude of hazard ratios (HRs) from the multiple HC analyses (HRs ranged from 1.02 to 1.06) were comparable with the reported trial HR (HR 0.91; 95% CI: 0.56, 1.49). This analysis demonstrates the feasibility and applicability of leveraging RWD in clinical trial design to supplement clinical trial control arms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California San Francisco, San Francisco, California, USA.
- Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Genentech, Inc., South San Francisco, California, USA.
- Roche Products Ltd, Welwyn Garden City, UK.
- F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
ORCID-Profile: Janet Lau, Mariano Ponz-Sarvise
Zitieren
APA
Ko, A. H., Oh, D. Y., Lau, J., Mhatre, S. K., Ci, B., Machado, R., Li, S., Bretscher, M. T., Reyes-Rivera, I., Zhu, J., Zhang, X., Patel, J., Psioda, M. A., & Ponz-Sarvise, M. (2025). Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/ II MORPHEUS Trial. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3528
Vancouver
Ko AH, Oh DY, Lau J, Mhatre SK, Ci B, Machado R, et al. Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/ II MORPHEUS Trial. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3528
BibTeX
@article{Ko2025,
author = {Ko, Andrew H and Oh, Do-Youn and Lau, Janet and Mhatre, Shivani K and Ci, Bo and Machado, Robson and Li, Shi and Bretscher, Michael T and Reyes-Rivera, Irmarie and Zhu, Jiawen and Zhang, Xiaosong and Patel, Jilpa and Psioda, Matthew A and Ponz-Sarvise, Mariano},
title = {Investigational Use of Real‐World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/ II MORPHEUS Trial},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3528}
}
EUVIMED